Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 64
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: jsubsetk
Page 1
Duchenne muscular dystrophy: pathogenesis and promising therapies.
Chang M, Cai Y, Gao Z, Chen X, Liu B, Zhang C, Yu W, Cao Q, Shen Y, Yao X, Chen X, Sun H. Chang M, et al. J Neurol. 2023 Aug;270(8):3733-3749. doi: 10.1007/s00415-023-11796-x. Epub 2023 Jun 1. J Neurol. 2023. PMID: 37258941 Review.
Therapeutic approaches for Duchenne muscular dystrophy.
Roberts TC, Wood MJA, Davies KE. Roberts TC, et al. Nat Rev Drug Discov. 2023 Nov;22(11):917-934. doi: 10.1038/s41573-023-00775-6. Epub 2023 Aug 31. Nat Rev Drug Discov. 2023. PMID: 37652974 Review.
Distal myopathy.
Savarese M, Jokela M, Udd B. Savarese M, et al. Handb Clin Neurol. 2023;195:497-519. doi: 10.1016/B978-0-323-98818-6.00002-9. Handb Clin Neurol. 2023. PMID: 37562883 Review.
Childhood muscular dystrophies.
Younger DS. Younger DS. Handb Clin Neurol. 2023;195:461-496. doi: 10.1016/B978-0-323-98818-6.00024-8. Handb Clin Neurol. 2023. PMID: 37562882 Review.
TOR1AIP1-Associated Nuclear Envelopathies.
Mackels L, Liu X, Bonne G, Servais L. Mackels L, et al. Int J Mol Sci. 2023 Apr 7;24(8):6911. doi: 10.3390/ijms24086911. Int J Mol Sci. 2023. PMID: 37108075 Free PMC article. Review.
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mercuri E, Vilchez JJ, Boespflug-Tanguy O, Zaidman CM, Mah JK, Goemans N, Müller-Felber W, Niks EH, Schara-Schmidt U, Bertini E, Comi GP, Mathews KD, Servais L, Vandenborne K, Johannsen J, Messina S, Spinty S, McAdam L, Selby K, Byrne B, Laverty CG, Carroll K, Zardi G, Cazzaniga S, Coceani N, Bettica P, McDonald CM; EPIDYS Study Group. Mercuri E, et al. Lancet Neurol. 2024 Apr;23(4):393-403. doi: 10.1016/S1474-4422(24)00036-X. Lancet Neurol. 2024. PMID: 38508835 Clinical Trial.
Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial.
Mendell JR, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, Alfano LN, Lewis S, Church K, Shell R, Potter RA, Griffin DA, Hogan M, Wang S, Mason S, Darton E, Rodino-Klapac LR. Mendell JR, et al. Muscle Nerve. 2024 Jan;69(1):93-98. doi: 10.1002/mus.27955. Epub 2023 Aug 14. Muscle Nerve. 2024. PMID: 37577753 Clinical Trial.
91 results